CytomX Therapeutics Stock Forecast

Stock Price Forecast

According to 9 analysts polled by S&P Global, CytomX Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $12.44. The average 1-year stock price forecast is 316.05% higher than the current stock price, while the lowest is $6.00 (+100.67%) and the highest is $16 (+435.12%).

Price Target: $12.44 (+316.05%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$6.00	$12.44	$12	$16
Change	+100.67%	+316.05%	+301.34%	+435.12%

Analyst Ratings

The average analyst rating for CytomX Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	5	5	6	6	6	6
Buy	2	2	3	3	3	3
Hold	2	2	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	9	9	9	9	9	9

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Robert Driscoll Wedbush	Wedbush	Buy Reiterates $11	Buy	Reiterates	$11	+267.89%	Jun 4, 2026
Kalpit Patel Wolfe Research	Wolfe Research	Buy Initiates $6	Buy	Initiates	$6	+100.67%	May 19, 2026
Matthew Biegler Oppenheimer	Oppenheimer	Buy Reiterates $12	Buy	Reiterates	$12	+301.34%	May 13, 2026
Mitchell Kapoor H.C. Wainwright	H.C. Wainwright	Buy Maintains $17 → $11	Buy	Maintains	$17 → $11	+267.89%	May 11, 2026
Edward Tenthoff Piper Sandler	Piper Sandler	Buy Reiterates $12	Buy	Reiterates	$12	+301.34%	May 8, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

33.68M

from 76.20M

-55.81%

from 76.20M

Revenue Next Year

29.65M

from 33.68M

-11.96%

from 33.68M

EPS This Year

-0.43

from -0.15

EPS Next Year

-0.51

from -0.43

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	37.31M	53.16M	101.21M	138.10M	76.20M	33.68M
Revenue Growth	-45.47%	42.48%	90.38%	36.45%	-44.82%	-55.81%
Gross Profit	37.31M	53.16M	101.21M	138.10M	76.20M	33.68M
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Income	-116.04M	-93.84M	-6.48M	25.00M	-19.56M	-92.93M
Net Income	-115.87M	-99.32M	-569.00K	31.87M	-17.37M	-86.09M
EPS	-	-	-	-	-0.15	-0.43
Free Cash Flow	-46.11M	-8.92M	43.66M	-44.20M	-43.21M	-60.75M
No. Analysts	-	-	-	-	-	7

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	80.0M
Avg	33.7M
Low	10.3M

Revenue Growth

Revenue Growth	2026	2027	2028
High	5.0%
Avg	-55.8%
Low	-86.5%

EPS Forecast

EPS	2026	2027	2028
High	-0.34
Avg	-0.43
Low	-0.51

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-